Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05983432 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial
NCT05983432 · ClinicalTrials.gov record · last posted 2026-01-29

Evaluate BL-B01D1 in Patients With Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors

StatusRecruiting
PhasePhase 1
Started2023-08-08
View on ClinicalTrials.gov ↗
from the ClinicalTrials.gov record
The objective of this study is to evaluate the safety, tolerability, and efficacy of BL-B01D1 in patients with Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors.

Amendment record 9 amendments on the ClinicalTrials.gov record

This ClinicalTrials.gov record has been amended 9 times since 2023-08-01; most recent amendment 2026-01-28. DataLookout shows field-level changes from the day a trial enters its daily monitoring; earlier amendments are counted here from the ClinicalTrials.gov version history. See every version on ClinicalTrials.gov ↗

2023-08-11
Status change Not Yet Recruiting→Recruitingv1
Trial Details
NCT Number NCT05983432
Lead Sponsor SystImmune Inc.
Conditions Non Small Cell Lung Cancer, Lung Cancer, Breast Cancer, Esophageal Cancer, Small Cell Lung Cancer, Nasopharyngeal Cancer, Head and Neck Squamous Cell Carcinoma, Prostate Adenocarcinoma +4 more
Enrollment 470 participants
Start Date 2023-08-08
Primary Completion 2026-12-31 (estimated)
Study Completion 2028-03-21 (estimated)
Updated on ClinicalTrials.gov 2026-01-29